Can Eltrombopag Tablets Be Crushed?
No, eltrombopag tablets should not be crushed when suspension is unavailable—use the powder for oral suspension (PfOS) formulation instead, as crushing tablets alters the drug's pharmacokinetic profile and bioavailability.
Rationale Based on FDA Drug Label and Research Evidence
The FDA-approved eltrombopag formulation is available as film-coated tablets for oral administration 1. The drug label describes these as "film-coated tablets" without any provision for crushing or alternative administration methods. Film-coated tablets are specifically designed to maintain their integrity during administration.
Critical Pharmacokinetic Considerations
Research directly comparing eltrombopag formulations demonstrates that the powder for oral suspension (PfOS) has 22% higher bioavailability than tablets (geometric mean ratio: 1.22; 90% CI: 1.08-1.38) 2. This indicates the two formulations are not bioequivalent, and crushing tablets would fundamentally alter drug delivery characteristics.
More importantly, crushing modified-release formulations changes dissolution profiles and drug release kinetics. While eltrombopag is not explicitly a modified-release product, research on crushing film-coated tablets shows that this practice:
- Alters surface morphology and particle size distribution 3
- Changes dissolution profiles across different pH ranges 3
- Results in unpredictable drug release patterns 3
Practical Clinical Approach
If suspension is unavailable:
Order the powder for oral suspension (PfOS) formulation - This is the FDA-approved alternative for patients who cannot swallow tablets 2
Do not crush tablets as a workaround - The altered bioavailability and unpredictable pharmacokinetics could result in:
- Subtherapeutic dosing (inadequate platelet response)
- Supratherapeutic dosing (risk of thrombotic complications) 1
If PfOS is truly unavailable and crushing is being considered out of desperation:
- Contact the manufacturer for guidance
- Consider alternative ITP therapies temporarily
- Document the clinical necessity and obtain informed consent about off-label administration
Important Caveats
The FDA label explicitly states administration instructions for intact tablets, requiring dosing "without a meal or with a meal low in calcium (≤ 50 mg)" and timing considerations with polyvalent cations 1. Crushing would make these critical administration requirements impossible to follow, as the crushed medication would have altered absorption characteristics and unpredictable interactions with food and supplements.
The risk of hepatotoxicity, thrombotic complications, and treatment failure makes crushing eltrombopag tablets an unacceptable practice 1, 4. Always use the appropriate formulation for the patient's needs.